

Paras Biopharma Joins PSL Alliance to Promote Worldwide reach out for Paras' Bioprocess Enzymes

Paras Biopharma announces that it is now a member of the Pivotal Scientific Limited (PSL) Alliance, a network of companies operating within the biotech market.

OULU, FINLAND, September 8, 2020
/EINPresswire.com/ -- Paras

Biopharmaceuticals Finland Oy (Paras Biopharma) is pleased to announce that it is now a member of the Pivotal

Scientific Limited (PSL) Alliance, a network of companies operating within the biotechnology market. As part of the Company's portfolio of microbial products, technologies and bioprocess enzymes, Paras Biopharma looks forward to reaching out to distributors and subsequently to the end users for its recombinant bioprocess enzymes.

PSL Alliance provides a platform for manufacturers, suppliers, and distributors to communicate with the aim to forge successful working relationships and worldwide reach out. Paras Biopharma believes that its association with PSL will enable Paras Biopharma to reach out to a larger customer base and will help researchers and companies in their biopharmaceutical development needs.

Together with its existing portfolio of recombinant enzymes that include "RapidTEV[®] (recombinant TEV protease) and RapidEK[®] (recombinant Enterokinase), the Paras Biopharma team has successfully developed a new addition, RapidZymo[®] (recombinant Zymolyase)".

The development of RapidZymo[®] complements the Company's existing portfolio of recombinant enzymes and proteases that are widely used for valuable biologics within research and development, including the cleavage of fusion proteins and removal of tags from recombinant proteins" said Dr Jordan Verrollot, Technical Associate, Paras Biopharmaceuticals.

"These enzymes are produced by Paras' proprietary technology platform and have been engineered for enhanced activity and greater stability. The Company is proud of the efforts its



microbial CDMO

Associates have made in developing these recombinant enzymes," said Dr Mark Jackson, Administration Lead, Paras Biopharmaceuticals.

"PSL appreciates and is pleased that Paras Biopharma has become a PSL Alliance member and it looks forward to working with the team at Paras Biopharma," said Richard Atkins, Commercial Director at Pivotal Scientific, UK.

About Paras Biopharmaceuticals Finland Oy

Paras Biopharma is a Finnish biopharmaceuticals company that started in 2012. Comprising of protein scientists, bioprocess engineers and technologists, Paras Biopharma's team has strong experience in developing biologics in the most efficient manner.

The Company's primary objective is to strive to create solutions through manufacturing innovations in the bioprocessing & bioproduction space for difficult-to-produce Biologics and Biosimilars.

Company main activities & offerings are in 3 major areas:

1. Contract development & microbial biologics manufacturing (CDMO)
2. Development of technologies for the production of biosimilars & complex biologics
3. Recombinant Bioprocess Enzymes

Paras Biopharma has a fully equipped microbial production facility in Finland for the production of recombinant therapeutic products. With a total floor area of 25,000 ft² and a classified cleanroom of 4,300 ft², other features include media and buffer preparation, live area (fermentation and harvest & extraction), purification suite (incl. +4°C cold room), final filtration and freeze-drying.

Paras Biopharma proprietary technology platform consists of Diabrid[®], Noblecleav[®], Biomultifold[®] and Cytofold StructQuant[®] Technologies.

<http://www.parasbiopharma.com/enzymes.php>

About Pivotal Scientific Limited (PSL) Alliance

Pivotal Scientific Limited is a unique biotechnology consultancy founded in 2008 by Tim Bernard, in response to a gap in the biotechnology market for a company that offered advice and support for small to medium-sized businesses operating within the research reagent sector. PSL's main objective is to assist companies in growing their brand and sales in this highly competitive market by supporting them at all stages of the business life cycle

<https://pivotalscientific.com/our-consultancy-services/the-psl-alliance/>

For more information on Paras Biopharma's enzymes and the company, kindly reach out to us at

BD@parasbiopharma.com. Please also visit our website <http://www.parasbiopharma.com>.

For other enquiries, please contact:

Dr Mark Jackson – email: mark.jackson@parasbiopharma.com

Dr Jordan Verrollot – email: jordan.verrollot@parasbiopharma.com

All the enzymes mentioned are for research & development purpose only and not for use in humans.

Mark Jackson

Paras Biopharmaceuticals Finland Oy

44 2905993

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/525792056>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.